Clinical Trial Update: Effect of Risedronate on Bone Morbidity in Fibrous Dysplasia of Bone [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial evaluating the effect of risedronate on bone morbidity in fibrous dysplasia of bone has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fibrous Dysplasia of Bone

Drugs mentioned

• risedronate (risedronate)

Snippet

Sponsor: Institut National de la Santé Et de la Recherche Médicale, France | Conditions: Fibrous Dysplasia of Bone | Phase 2, Phase 3 | Status: COMPLETED